MBX Biosciences, Inc. Common Stock (MBX)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
Cash on hand (at last report)			132.87 mm
Cash burn (monthly)			6.54 mm
Cash used (since last report)			33.22 mm
Cash remaining			99.65 mm
Runway (months of cash)			15.2

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

MBX institutional ownership history Ownership history

13F holders	Current	Change
Total holders	48	NEW
Opened positions	48	NEW
Closed positions	0
Increased positions	0
Reduced positions	0

13F shares	Current	Prev Q	Change
Total value	751.05 bn	0.00	NEW
Total shares	42.37 mm	0.00	NEW
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Frazier Life Sciences Management	5.99 mm	$155.50 bn	NEW
Frazier Life Sciences Public Fund	4.55 mm	$102.60 mm	NEW
Orbimed Advisors	3.81 mm	$99.04 bn	NEW
NEA Management	3.61 mm	$93.90 bn	NEW
New Enterprise Associates 17	3.61 mm	$80.57 mm	NEW
Deep Track Capital	3.02 mm	$78.43 bn	NEW
Wellington Management	2.94 mm	$74.26 bn	NEW
NVP Associates	2.14 mm	$55.50 bn	NEW
Norwest Venture Partners XVI	2.14 mm	$47.62 mm	NEW
Wellington Biomedical Innovation Master Investors	1.79 mm	$38.67 mm	NEW

Largest transactions	Shares	Bought/sold	Change
Frazier Life Sciences Management	5.99 mm	+5.99 mm	NEW
Frazier Life Sciences Public Fund	4.55 mm	+4.55 mm	NEW
Orbimed Advisors	3.81 mm	+3.81 mm	NEW
NEA Management	3.61 mm	+3.61 mm	NEW
New Enterprise Associates 17	3.61 mm	+3.61 mm	NEW
Deep Track Capital	3.02 mm	+3.02 mm	NEW
Wellington Management	2.94 mm	+2.94 mm	NEW
NVP Associates	2.14 mm	+2.14 mm	NEW
Norwest Venture Partners XVI	2.14 mm	+2.14 mm	NEW
Wellington Biomedical Innovation Master Investors	1.79 mm	+1.79 mm	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

MBX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
18 Feb 25	Orbimed Advisors	Common Stock	Buy	Acquire P	Yes	No	10.84	94,100	1.02 mm	747,887
18 Feb 25	Orbimed Advisors	Common Stock	Buy	Acquire P	Yes	No	10.84	49,070	531.92 k	3,255,000
18 Feb 25	Gordon Carl L	Common Stock	Buy	Acquire P	Yes	No	10.84	94,100	1.02 mm	747,887
18 Feb 25	Gordon Carl L	Common Stock	Buy	Acquire P	Yes	No	10.84	49,070	531.92 k	3,255,000
14 Feb 25	Orbimed Advisors	Common Stock	Buy	Acquire P	Yes	No	9.85	29,540	290.97 k	3,205,930
14 Feb 25	Orbimed Advisors	Common Stock	Buy	Acquire P	Yes	No	9.9	17,962	177.82 k	3,176,390
14 Feb 25	Gordon Carl L	Common Stock	Buy	Acquire P	Yes	No	9.85	29,540	290.97 k	3,205,930
14 Feb 25	Gordon Carl L	Common Stock	Buy	Acquire P	Yes	No	9.9	17,962	177.82 k	3,176,390
4 Feb 25	P. Kent Hawryluk	Common Stock	Buy	Acquire P	Yes	No	10.69	50,000	534.50 k	448,277
3 Feb 25	Salomon Azoulay	Stock Option Common Stock	Grant	Acquire A	No	No	10.49	90,000	944.10 k	90,000

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Earnings Scheduled For February 13, 2025

13 Feb 25

12 Health Care Stocks Moving In Thursday's Pre-Market Session

6 Feb 25

12 Health Care Stocks Moving In Thursday's Pre-Market Session

6 Feb 25

Why Logility Supply Chain Solutions Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket

27 Jan 25

Applied Digital, Vericel, Calavo Growers And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

15 Jan 25

Press releases

From Benzinga Pro

MBX Biosciences to Participate in March Investor Conferences

18 Feb 25

CARMEL, Ind., Feb. 18, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the